Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease
- PMID: 33406628
- PMCID: PMC7823437
- DOI: 10.3390/metabo11010029
Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease
Abstract
The gut microbiome can impact brain health and is altered in Parkinson's disease (PD). The vermiform appendix is a lymphoid tissue in the cecum implicated in the storage and regulation of the gut microbiota. We sought to determine whether the appendix microbiome is altered in PD and to analyze the biological consequences of the microbial alterations. We investigated the changes in the functional microbiota in the appendix of PD patients relative to controls (n = 12 PD, 16 C) by metatranscriptomic analysis. We found microbial dysbiosis affecting lipid metabolism, including an upregulation of bacteria responsible for secondary bile acid synthesis. We then quantitatively measure changes in bile acid abundance in PD relative to the controls in the appendix (n = 15 PD, 12 C) and ileum (n = 20 PD, 20 C). Bile acid analysis in the PD appendix reveals an increase in hydrophobic and secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA). Further proteomic and transcriptomic analysis in the appendix and ileum corroborated these findings, highlighting changes in the PD gut that are consistent with a disruption in bile acid control, including alterations in mediators of cholesterol homeostasis and lipid metabolism. Microbially derived toxic bile acids are heightened in PD, which suggests biliary abnormalities may play a role in PD pathogenesis.
Keywords: Parkinson’s disease; appendix; bile acids; gut; microbiome.
Conflict of interest statement
P.B. has received commercial support as a consultant from Axial Biotherapeutics, Calico, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S, Idorsia and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics and is on the steering committee of the NILO-PD trial. S.G. receives commercial support as a consultant from Coleman Research and Biogen. No other authors have conflicts of interest.
Figures




References
-
- Kim S., Kwon S.-H., Kam T.-I., Panicker N., Karuppagounder S.S., Lee S., Lee J.H., Kim W.R., Kook M., Foss C.A., et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron. 2019;103:627–641.e627. doi: 10.1016/j.neuron.2019.05.035. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials